Opioid prescriptions significantly higher for patients with lifelong disabilities, study finds

2022-07-07
People with two pediatric-onset neurodevelopmental disorders are prescribed opioids at a rate up to five times higher than those who do not have those conditions, a new study finds. Researchers say the findings raise concerns over addiction, overdose and mental health issues. A Michigan Medicine study finds that people with two pediatric-onset neurodevelopmental disorders are prescribed opioids at significantly higher rates than those without the conditions, raising concerns over addiction, overdose and mental health issues. Researchers analyzed prescriptions of opioids from private insurance claims of over 22,000 patients with cerebral palsy or spina bifida, and more than 930,000 patients without the conditions. They found that oral morphine equivalents, derived from medications such as oxycodone, codeine and morphine, were prescribed to patients with cerebral palsy and spina bifida at a rate up to five times higher than patients who do not have those conditions. The higher prescription patterns spanned across people with no pain, isolated and chronic pain, according to results published in Heliyon. "Our findings are of great concern, given the known links between persistent opioid use and psychiatric conditions, as well as with overdose mortality," said Mark Peterson, Ph.D., M.S., lead author of the paper and an associate professor of physical medicine and rehabilitation at University of Michigan Medical School. Chronic pain is the most commonly reported symptom among patients with cerebral palsy, a neurological condition caused by abnormalities in the brain, and spina bifida, a neural tube defect that can damage the spinal cord and nerves. Pain in these individuals may arise from several issues, including muscle spasticity, arthritis and invasive surgical procedures. Previous studies found that more than 40% of all Medicaid beneficiaries with a disability took opioid pain relievers, with more than 20% reporting chronic opioid use. The research team raises concerns over whether long-term opioid use is appropriate for the treatment of non-cancer-related chronic pain. Future studies must examine the effectiveness of non-opioid pain medications and alternative pain management strategies for adults living with cerebral palsy and spina bifida, says co-author Edward Hurvitz, M.D., chair of the U-M Health Department of Physical Medicine and Rehabilitation and a professor at U-M Medical School. "Improving clinical pain screening strategies and developing efficient referral resources for appropriate pain management may help reduce the burden of opioid addiction and overdose in these populations by matching treatments to underlying pain mechanisms," Hurvitz said. Additional authors include: Neil Kamdar, M.A., Jeidi J. Haapala, M.D., Chad Brummett, M.D., all of Michigan Medicine This research was developed in part under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR #90RTHF0001-01-00).
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。